Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury  by Rubenstein, Mark H. et al.
Short-Term Intravenous Eptifibatide Infusion
Combined With Reduced Dose Recombinant
Tissue Plasminogen Activator Inhibits Platelet
Recruitment at Sites of Coronary Artery Injury
Mark H. Rubenstein, MD,* Aloke V. Finn, MD,* Robert C. Leinbach, MD, FACC,*
Stanley Hollenbach, PHD,† H. Thomas Aretz, MD,* Renu Virmani, MD,‡ Herman K. Gold, MD, FACC*
Boston, Massachusetts; and Washington, DC
OBJECTIVES This study was designed to determine in a dog model of coronary thrombosis whether
short-term eptifibatide (Ep) combined with low-dose plasminogen activator (rt-PA) inhibits
platelet recruitment at sites of endothelial damage after normalization of platelet function.
BACKGROUND Ep plus reduced-dose rt-PA has not previously been shown to render a recanalized coronary
artery resistant to platelet recruitment after normalization of platelet function.
METHODS Inhibition of platelet recruitment was studied by scanning electron microscopy (SEM) in a
canine model of left anterior descending (LAD) thrombosis. In phase I treatment groups
were: 1) Ep (n  6); 2) Ep  rt-PA (n  6); 3) rt-PA (n  6); and 4) placebo (n  4).
Coronary blood flow was monitored and LAD segments excised for SEM after 90-min
infusion of study drug. In phase II, dogs were randomized to Ep alone (n  5) or to Ep 
rt-PA (n  5). Coronary blood flow was monitored during and 120 min after cessation of
drug when platelet function had returned to normal and LAD segments were excised.
RESULTS All animals except placebo showed reflow. In phase I, SEM showed an absence of platelet
aggregates with Ep alone and with Ep  rt-PA, but not with rt-PA alone. In phase II, SEM
showed an intimal surface devoid of mural thrombus and platelet aggregates only in Ep 
rt-PA treated arteries. Ep-alone treated arteries showed new platelet aggregates at sites of
residual mural thrombus.
CONCLUSIONS Short-term infusion Ep plus low-dose rt-PA acutely neutralizes the ability of damaged
endothelial surfaces to recruit new platelets by inhibiting platelet aggregation and eliminating
residual mural thrombus. (J Am Coll Cardiol 2004;43:287–94) © 2004 by the American
College of Cardiology Foundation
The pathophysiologic event initiating acute myocardial
infarction (MI) is most often rupture of a vulnerable
atherosclerotic plaque, leading to formation of an occlusive
intraluminal thrombus (1–3). At the site of endothelial
disruption, there is immediate adherence and deposition of
activated platelets on the injured arterial surface (4). The
progression of mural to occlusive thrombus depends upon
the thrombogenicity of the damaged surface, the capacity of
the endogenous fibrinolytic system to limit thrombus for-
mation, and the severity of the stenosis (5,6). Although
exogenous plasminogen activators, in conjunction with as-
pirin and heparin, are widely used to restore flow, they do
not fully address the thrombogenicity of the damaged
arterial surface. The exposed subendothelial structures and
the reservoir of thrombin within the residual mural throm-
bus provide the substrate for recurrent thrombus formation
at the site of arterial damage (7–9). The reaccumulation of
platelet-rich thrombus on this substrate predisposes to
reocclusion and recurrent ischemic events (10–12). The
neutralization of these residual thrombogenic stimuli is
likely required to maintain coronary patency following
successful thrombolysis for acute MI.
Our previous studies in a canine model of coronary
thrombosis have demonstrated that platelet glycoprotein
(GP) IIb/IIIa receptor blockade using the 7E3 antibody in
combination with low-dose plasminogen activator acceler-
ates reflow and prevents coronary reocclusion (10,13–15).
The prevention of reocclusion in this model required plate-
let inhibition with 80% GP IIb/IIIa receptor blockade.
However, because of the prolonged blockade of the GP
IIb/IIIa receptor by the 7E3 antibody, we could not
determine whether failure of the damaged arterial endothe-
lium to recruit new platelets was a consequence of acute
neutralization of the thrombogenic surface or simply a result
of persistent receptor blockade.
Eptifibatide (Ep) is a reversible platelet GP IIb/IIIa
receptor antagonist with a short half-life. In the first phase
of the present study, we investigated the efficacy of a 90-min
continuous intravenous infusion of Ep alone and in combi-
nation with reduced-dose recombinant tissue plasminogen
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activator (rt-PA) to: 1) induce reflow with complete lysis of
intraluminal and mural thrombus, 2) inhibit the recruitment
of platelets onto the damaged endothelial surface, and 3)
prevent coronary reocclusion in the presence of high-grade
coronary stenosis. In the second phase, we determined: 1)
whether a short-term infusion of Ep alone would acutely
neutralize vessel wall thrombogenicity (in the presence of
residual mural thrombus), or 2) whether the addition of
low-dose exogenous plasminogen activator to Ep would be
required to eliminate residual mural thrombus in order to
completely neutralize vessel wall thrombogenicity. The
purpose of this study was to determine whether short-term
Ep in concert with reduced-dose plasminogen activator
could acutely prevent platelet recruitment, new thrombus
formation, and reocclusion at sites of endothelial damage
despite the return of platelet function to normal.
METHODS
Phase I
Observations during Ep infusion. Animals used in this
study were maintained in accordance with the “Guide for
the Care and Use of Laboratory Animals” (National Re-
search Council, revised 1996). A total of 22 adult mongrel
dogs (20 to 25 kg) were anesthetized with intravenous
sodium pentobarbital (35 mg/kg), intubated, and artificially
ventilated. A left thoracotomy was performed, and the
internal mammary artery was cannulated for continuous
blood pressure monitoring. The experimental preparation,
consisting of occlusive left anterior descending (LAD)
coronary artery thrombosis with endothelial damage and
superimposed distal stenosis, was prepared as previously
described (10). Briefly, the isolated LAD segment was
traumatized by four consecutive external compressions with
blunt forceps during 3 to 5 s. Snare occlusions were made
distal to the flow probe and proximal to the constriction site.
Thrombin, 0.1 ml of 100 U/ml (Thrombinar, Armour
Pharmaceutical, Kankakee, Illinois), mixed with 0.3 ml
blood, was injected through the side branch catheter into
the emptied coronary artery segment. After 5 min the
proximal snare was released; 2 min later, the distal tourni-
quet was released. Total occlusion of the artery was dem-
onstrated by ultrasonic flow probe. Twenty minutes after
formation of a stable, occlusive erythrocyte-rich coronary
artery thrombus, heparin (3,000 U) and aspirin (Aspegic, 10
mg/kg) were administered by intravenous (IV) bolus injec-
tion. Upon persistence of occlusion, experimental treatment
was initiated 10 min later. The initial coronary occlusion
and subsequent reflow in the artery were documented and
monitored continuously by an electromagnetic flow probe
during the infusion of the study drug.
Intravenous infusions were performed with a constant
rate infusion pump. Additional 1,000 U bolus injections of
heparin were administered as needed to maintain the
activated clotting time (ACT) 250 s. Reflow time was
defined prospectively as the interval between the initiation
of eptifibatide (Group I), rt-PA (Groups II and III), or
placebo (Group IV) therapy and the recurrence of blood
flow. Baseline flow was measured after placement of the
external constrictor and before total occlusion of the artery.
Reflow was defined as the return of25% of baseline blood
flow. Reocclusion was defined as the reduction of coronary
blood flow to 25% of baseline. Coronary artery patency
status was categorized as follows: 1) persistent patency:
persistent flow without reocclusion after initial reflow; 2)
cyclic reflow and reocclusion: alternating cycles of reocclu-
sion after initial reflow; 3) persistent occlusion: no recur-
rence of blood flow.
Treatment. Initial dose-finding studies determined that IV
Ep administration of 0.5 mg/kg of body weight followed by
a continuous infusion of 6 g/kg/min for 90 min was the
minimally effective dose to inhibit completely adenosine
diphosphate-induced platelet aggregation ex vivo when the
sample was collected in heparin. rt-PA was administered as
a 0.45 mg/kg of body weight IV bolus (1/4 of the full canine
thrombolytic dose) every 15 min until reflow, not exceeding
a maximum of four injections. A comparative study of the
following treatments for coronary thrombolysis was then
performed: Group I) eptifibatide alone, n  6; Group II)
eptifibatide  rt-PA, n  6; Group III) rt-PA alone, n 
6; Group IV) placebo (IV saline bolus plus continuous
infusion), n  4.
Hemostasis analysis. Platelet counts and hematocrit mea-
surements were determined on blood samples collected into
0.05 ml (15%) liquid ethylenediaminetetraacetate (K3
EDTA) at baseline and immediately before cessation of
therapy at 90 min. Activated clotting time values were
determined on 1 ml whole blood samples in a Hemochron
analyzer. Blood samples (10 ml) for platelet aggregation
were collected into 4 U/ml heparin containing 150 KIU/ml
aprotinin at pretreatment, 10, 30, and 60 min after start of
treatment, and immediately before cessation of infusion at
90 min. Platelet-rich plasma was prepared and tested for
platelet aggregation induced by a threshold concentration of
ADP (Sigma Diagnostics, St. Louis, Missouri) in a dual-
channel aggregometer (Chrono-log Corp., Havertown,
Pennsylvania) at 37°C with constant stirring, as previously
described (16). Quantitative analysis of aggregation was
determined as the maximal percent change in transmittance
Abbreviations and Acronyms




LAD  left anterior descending
MI  myocardial infarction
rt-PA  tissue plasminogen activator
SEM  scanning electron microscopy
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(% delta T), measured from baseline to the lowest portion of
the curve, after addition of agonist. Template bleeding times
were measured at baseline, 30, and 60 min after the start of
therapy, and immediately before cessation of infusion at 90
min, as previously described (15).
Pathologic examination. At the end of the experiment,
dogs were euthanized with an overdose (100 mg/kg IV) of
pentobarbital. The LAD coronary artery was then perfusion
fixed in situ with 5% buffered formaldehyde. The throm-
bosed, stenotic, and poststenotic segments, as well as the
entire distal segment of the LAD, were then removed intact
and preserved. LAD segments were post-fixed in 4%
glutaraldehyde overnight. Specimens were then dehydrated,
critical point dried, mounted individually, and examined by
scanning electron microscopy (SEM). Micrographs were
interpreted by a cardiac pathologist, blind to the treatment
protocols.
Statistical analysis. Results are expressed as mean values
standard deviation (SD). The significance of differences
between groups was determined by Student t test for
unpaired values. A paired t test was used for determination
of intragroup differences. Fisher exact test was used to
compare the significance of differences in the frequencies of
reflow and reocclusion in the four treatment groups.
Phase II
Observations after cessation of Ep infusion. After the
initial 22 experiments, 10 additional dogs were assigned to
receive either Ep  rt-PA (n  5) or Ep alone (n  5).
Experimental procedures were performed as described ear-
lier, but coronary blood flow was monitored continuously
for an additional 120 min after cessation of the Ep infusion.
Heparin continued to be administered as needed to main-
tain an ACT 250 s. ADP-induced platelet aggregation
was measured at baseline, 10 min after initiation of eptifi-
batide therapy, immediately before cessation of infusion at
90 min, and then at 30, 60, 90, and 120 min after
discontinuation of Ep infusion.
Venous blood samples (3 ml) for measurement of plasma
Ep levels were collected into 0.05 ml (15%) liquid EDTA at
baseline, 30, 45, 60, and 90 min after initiation of Ep and
then at 30, 60, 90, and 120 min after cessation of infusion.
The thrombosed, stenotic, and poststenotic segments, as
well as the entire distal segment of the LAD from all 10
animals, were removed intact and preserved. The LAD
segments were post-fixed in 4% glutaraldehyde overnight.
Specimens were then dehydrated, critical point dried,
mounted individually, and examined by SEM. Micrographs




Observations during Ep infusion. Experiments were first
performed to determine whether Ep enhanced the ability of
rt-PA to lyse thrombi. The results for coronary artery blood
flow and patency status in the initial 22 dogs are presented
in Table 1. All animals, except those given placebo, showed
reflow. In combination with heparin and aspirin, Ep alone
(Group I) produced reflow at 42  28 min and rt-PA alone
(Group III) at 20  17 min. The combination of Ep and
only a single injection of rt-PA (Group II) significantly
accelerated reflow to 5  3 min (p  0.002). In comparison
to Group III dogs, combined therapy with Ep reduced the
rt-PA dose required to initiate reflow. Statistical analysis
comparing all experiments yielded significant overall differ-
ences with respect to patency status (p  0.001). Coronary
reocclusion was not observed in any dog given Ep, but
occurred cyclically in four of six rt-PA-alone treated animals
(p  0.001).
Platelet aggregation and bleeding time. Enhancement of
lysis was observed at doses of drug that inhibited platelet
aggregation and prolonged bleeding time (Table 2). Com-
plete abolition of ADP-induced platelet aggregation was
observed in samples collected 10 min after the start of Ep
infusion and persisted for the 90-min duration of treatment.
Platelet aggregation did not change significantly from base-
line values in rt-PA or placebo-treated dogs. Platelet counts
and hematocrit measurements (data not shown) were within
normal limits and remained unchanged from baseline
values.
Pathology. Significant mural disruption was observed in all
arteries. Arterial segments of persistently patent arteries in all
animals revealed an irregular, denuded endothelium and areas
of exposed media. Both the composition and amount of
residual thrombus within the artery correlated with the type of
treatment (Table 1). Animals treated with eptifibatide alone
Table 1. Reflow and Patency Status
Group Agent
Reflow Patency Status†
PathologyN/total N Time (min) PO CR PP
I Ep 6/6 42  28* — — 6 MT,ER
II Ep  rt-PA 6/6 5  3* — — 6 Clean
III rt-PA 6/6 20  17 — 4 2 MT,PR
IV Saline 0/4 — 4 — — OT
*p  0.002; †p  0.001. Values are mean  SD.
CR  cyclic reflow; Ep  eptifibatide; ER  erythrocyte-rich; MT  mural thrombus; OT  occlusive thrombus; PO  persistent occlusion; PP  persistent patency;
PR  platelet-rich; rt-PA  recombinant tissue plasminogen activator.
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(Group I) demonstrated residual erythrocyte-rich mural
thrombus. The areas of exposed media and denuded endothe-
lium were partially covered by platelets in an incomplete
monolayer with no evidence of platelet clumping or aggrega-
tion. In contrast, animals treated with combination therapy
(Group II) demonstrated a luminal surface that was predom-
inantly clean, with a few scattered platelets and red blood cells,
and minimal adherent mural thrombus without red cells or
fibrin. Animals treated with rt-PA alone (Group III) contained
platelet-rich mural thrombi. Finally, in placebo-treated animals
(Group IV), the lumen was completely occluded with
erythrocyte-rich thrombus.
Phase II
Observations after cessation of Ep infusion. First, coronary
reflow was initiated in all dogs at 4  1 min in the Ep 
rt-PA group and at 44  13 min in the Ep-alone group.
Similar to the results from phase I, coronary artery patency
was maintained throughout the 90-min infusion in all 10
dogs.
Experiments were then performed to determine the time
required for restoration of platelet function following ces-
sation of Ep infusion. Table 3 shows the time-dependent
loss of Ep-induced inhibition of platelet aggregation: by 120
min, plasma levels of Ep had declined to 90  34 ng/dl
from the 944  326 ng/dl achieved during infusion. The
concentration of drug required to inhibit 50% (IC50) of
ADP-induced platelet aggregation in dogs is 627  63 nM
using heparin anticoagulation. Thus, even at 90 34 ng/ml
(approximately 100 nM), there would be 10% inhibition
of platelet aggregation. Table 3 also shows a time-
dependent recovery of platelet function: by 120 min, platelet
aggregation had returned to 86  28% of normal from the
complete inhibition achieved during infusion.
Pathology. To determine whether normally functioning
platelets participated in thrombosis, experiments were per-
formed to determine whether the arteries remained patent
following cessation of the eptifibatide infusion. Although
flow analysis revealed that all 10 arteries remained patent
during the 120-min observation period, the SEM high-
lighted the differences between the two groups.
Arterial segments obtained from the 10 dogs at 120 min
after the cessation of Ep when platelet function had returned
nearly to baseline were analyzed by SEM. In dogs treated with
Ep alone, a significant nonocclusive thrombus persisted at the
site of thrombin injection. Additionally, there were newly
adherent platelet aggregates on the residual thrombus and at
multiple sites of endothelial disruption (Fig. 1). These SEM
images are consistent with a thrombus in evolution where a
retained, incompletely lysed, fibrin-rich, red-cell-rich throm-
bus functions as a nidus for the recruitment of activated
platelets in the absence of GP IIb/IIIa receptor platelet
blockade. In the dogs treated with Ep and rt-PA, SEM
demonstrated an intimal surface with irregular, denuded en-
dothelium and areas of exposed media. The luminal surface
showed minimal intraluminal or mural thrombus without red
cells or platelet adherence. Areas of exposed media showed
either complete absence of cells of hematologic origin or
scattered foci of platelet adherence (Fig. 2). Even in the setting
of extensive intimal disruption with circumferential tears and
high-grade stenosis, the injured de-endothelialized surface did
not recruit new mural thrombus or new platelet aggregates at a
time when platelet function was rapidly returning to baseline
after cessation of the Ep infusion.
DISCUSSION
In the present study, we used a canine model of coronary
thrombosis with endothelial disruption and superimposed
distal stenosis to demonstrate that short-acting, reversible
Table 2. Platelet Aggregation and Bleeding Time
Group Agent
Platelet Aggregation (%)* Bleeding Time (min)
0 min 10 min 30 min 60 min 90 min 0 min 30 min 60 min 90 min
I Ep 75  16 0 0 0 0 1 11  6 11  6 9  7
II Ep  rt-PA 71  24 0 0 0 0 2  1 11  5 11  5 8  6
III rt-PA 65  22 – 67  31 71  24 66  23 1 3  2 4  4 2  2
IV saline 68  11 – 63  12 59  19 69  11 1 2  1 1 1
*% light transmittance normalized to base line values. Values are mean  SD.
Abbreviations as in Table 1.
Table 3. Platelet Aggregation and Eptifibatide Levels After Cessation of Eptifibatide Infusion
Time Post Infusion (min)
0 30 60 90 120
Platelet aggregation (%)* 0 52  10 48  26 68  29 86  28
Plasma eptifibatide concentration
(ng/ml)
944  326 310  182 215  122 116  45 90  34
*% light transmittance normalized to base line values. Values are mean  SD
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GP IIb/IIIa inhibitor Ep, in combination with rt-PA, can
acutely render a recanalized coronary artery resistant to
platelet recruitment, new thrombus formation, and reocclu-
sion despite the return of platelet function to normal. This
model, with its exposed subendothelial structures, circum-
ferential tears, residual mural thrombus, and high-grade
Figure 1. A is a low-power view of the longitudinally cut proximal left anterior descending coronary artery from a dog assigned to receive eptifibatide alone
(in Phase II) showing presence of thrombus at the site of the side branch catheter through which thrombin was infused. Just distal to the thrombus, the
traumatized left anterior descending coronary artery is seen. B and E are high-power views of the thrombus, showing platelet aggregation with fibrin strands
and an occasional red cell. (C and F are high-power views of an area of the vessel severely damaged from crush injury, demonstrating disrupted endothelium
covered by a thick layer of aggregated platelets within a fibrin mesh. D and G are high-power views from a more distal, less severely injury vessel segment
showing a fibrin mesh with platelet adherence to the underlying collagen at the site of vessel injury.
Figure 2. A is a low-power view of the longitudinally cut proximal left anterior descending coronary artery from a dog assigned to receive eptifibatide  rt-PA
in Phase II. There is virtually no visible thrombus in marked contrast to that seen in Figure 1. B and E are high-power views of the small thrombus (arrow) showing
a few scattered platelets adhering to the minimal thrombus. C and F are high-power views of an area of the vessel severely damaged from crush injury with absence
of endothelium and exposure of the underlying collagen with only an occasional platelet adhering to the collagen and rare red cells. D and G are high-power views
from a more distal area of the vessel with focal loss of endothelium, demonstrating only rare platelets adhering to the underlying surface. Compared to Figure 1,
high-power views F and G demonstrate a marked reduction in the number of platelets adhering to two different segments of comparable vessel wall injury.
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stenosis, constitutes a highly thrombogenic environment,
thus representing a stringent challenge for the efficacy of a
pharmacologic strategy to prevent recurrence of thrombus
formation and acute reocclusion by neutralizing residual
thrombogenicity at the site of endothelial disruption.
In the first phase of this study, we confirmed a principle
previously established using 7E3 antibody and reduced dose
rt-PA in our canine model of MI (14). During low-dose
thrombolysis and high-level GP IIb/IIIa receptor blockade,
SEM of the damaged arterial segment demonstrates a pre-
dominantly clean luminal surface, devoid of residual thrombus,
with only select areas covered by scattered platelets.
In the absence of exogenous plasminogen activator, ep-
tifibatide alone accelerated endogenous thrombolysis. How-
ever, SEM demonstrated erythrocyte-rich mural thrombus,
indicative of thrombus incompletely lysed by the endoge-
nous fibrinolytic system. Although reocclusion was pre-
vented with a continuous Ep infusion, exogenous plasmin-
ogen activator was required for complete clearance of the
coronary thrombus in this model.
Two hours after cessation of the eptifibatide infusion in
the combination Ep  rt-PA group, SEM again demon-
strated a predominantly clean surface, devoid of residual
thrombus, with only a few areas covered with scattered
platelets. Despite the return of normal platelet function, the
subendothelial structures and circumferential tears in the
damaged arterial segment failed to recruit new aggregates of
platelets to the site of injury. This finding suggests that the
damaged endothelial surface, even in the presence of high-
grade stenosis, is no longer capable of recruiting and
promoting platelet aggregation at the site of exposed sub-
endothelial matrix.
In contrast, 2 h after cessation of Ep in the Ep-alone
group, SEM demonstrated persistent residual erythrocyte-
rich mural thrombus at sites of endothelial damage. At these
sites of retained thrombus, new platelet aggregates and
clumps were seen. Our findings demonstrate that high-level
GP IIb/IIIa receptor blockade, combined with heparin and
aspirin, is not sufficient to acutely neutralize the thrombo-
genicity of a damaged vessel wall in the presence of retained
mural thrombus.
Multiple studies have established that the thrombogenic-
ity of exposed subendothelial structures at the site of arterial
wall damage is transient (17–20). Groves et al. (18) showed
that after 8 h of platelet inhibition with prostaglandin, the
damaged neointima in rabbits loses its ability to interact
with platelets. Piepegras (19) showed that injured cat
endothelium was nonreactive to platelets after 6 h of
heparin. Wilentz et al. (20) subsequently demonstrated that
most platelet deposition after deep balloon injury occurred
within 30 min of endothelial disruption and returned to
baseline within 4 h. Thus, if platelets are inhibited for a
sufficient period of time following vessel wall injury, the
injured wall loses its capacity to activate circulating platelets
and its ability to form mural thrombus at the site of exposed
subendothelium.
Residual mural thrombus alone, despite an ACT250, can
act as a potent stimulus for the recruitment of new platelets.
Badimon et al. (21) have shown, in an isolated perfusion
chamber, that formed thrombus is an even more potent
stimulus to platelet recruitment than the exposed subendothe-
lial structures. This intense thrombogenicity is primarily re-
lated to clot-bound thrombin (22) located in the interstices of
the fibrin-rich thrombus (23,24), thereby protecting it from
exposure to both heparin and antithrombin III.
Several studies have examined the effectiveness of GP
IIb/IIIa platelet inhibition on prevention of thrombosis in
canine models of arterial injury. In these models of coronary
thrombosis induced by electrical injury (25,26) or segmental
inversion (27,28), pretreatment of animals with 7E3 anti-
body consistently prevented coronary occlusion for 5 h
following arterial damage during maximal GP IIb/IIIa
receptor blockade. However, when animals were monitored
beyond 5 h, reocclusion occurred in 22% to 60% of animals
within one to six days (26,27). All arterial segments studied
showed the presence of intraluminal macroscopic thrombus.
Subsequently, Rote et al. (29) gave sequential rt-PA and
7E3 to dogs with electrically induced LAD thrombosis.
During five days of follow-up, although all vessels remained
patent, considerable macroscopic thrombus remained. In
these studies, coronary patency was used as a surrogate
marker for the recurrence of mural and intraluminal throm-
bus. Patency, however, does not indicate the absence of new
thrombus formation. An artery may be patent, but, by
continuing to recruit platelets on residual thrombus, may
become susceptible to later reocclusion. Thus, patency in
these studies is not a specific measure of the ability of the
damaged arterial surface to recruit platelets. Scanning elec-
tron microscopy offers a more precise measure of the
presence of thrombus, allowing direct visualization of the
damaged endothelial surface and quantitation of fibrin and
platelet aggregates. Our SEM-based demonstration of in-
hibition of platelet deposition at sites of injury establishes
the principle that combination therapy acutely neutralizes
the ability of the damaged endothelial surface to recruit new
platelets by both inhibiting platelet aggregation and elimi-
nating residual mural thrombus. This is the first study using
an animal model of coronary artery thrombosis and SEM to
demonstrate the ability of combination therapy to render a
damaged endothelial surface resistant to new platelet dep-
osition when platelet function has returned to normal.
This study is relevant to a continuing problem in the
management of patients with ST elevation MI treated with
thrombolytic therapy. In the early period after successful
reflow, there is persistent instability of the culprit lesion
because of residual high-grade stenosis and retained thrombus
leading to reinfarction-recurrent ischemia. These complica-
tions were significantly reduced by combination therapy in
GUSTO-V (30) and ASSENT-3 (31), although mortality was
not significantly altered. Our findings do provide an additional
biologic rationale for a pharmacologic strategy that not only
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accelerates thrombolysis but also may provide short-term
stability to a reperfused culprit lesion, permitting safe and
deliberate transfer of patients to angioplasty-capable centers for
definitive lesion stabilization.
STUDY LIMITATIONS
In the second phase of the study, our open-chest canine
model of MI does not permit the long-term study of various
reflow strategies. Nevertheless, the SEM at 2 h post
cessation of Ep, when platelet function had returned to
normal, reflects the state of the damaged endothelium in the
absence of platelet inhibition. We do not know how the
cellular biology of the damaged endothelium would have
evolved had more time elapsed before sacrifice. Further
studies will need to focus on the ability of this combination
therapy to sustain long-term arterial patency.
CONCLUSIONS
Short-term, high level platelet GP IIb/IIIa receptor blockade
combined with low-dose plasminogen activator is capable of
reflowing and acutely rendering the injured and stenotic canine
coronary artery resistant to platelet recruitment after return of
normal platelet function. However, if thrombolysis is incom-
plete, the residual mural thrombus serves as a nidus for platelet
reaccumulation. Thus, our study provides an additional ratio-
nale for the use of combined therapy to promote temporary
stabilization of the culprit lesion, permitting transfer for per-
cutaneous coronary intervention.
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